阿斯利康与甲骨文合作开展人工智能驱动的临床试验

路透中文

昨天

<a href="https://laohu8.com/S/AZN">阿斯利康</a>与<a href="https://laohu8.com/S/ORCL">甲骨文</a>合作开展人工智能驱动的临床试验

路透10月20日 - 阿斯利康（AstraZeneca） AZN.L 周二表示，该公司正与甲骨文（Oracle） ORCL.N 合作，利用人工智能和真实世界数据来筛选符合条件的临床试验患者并监测安全性信号等，以此提升临床研究水平。

此次合作将结合阿斯利康在药物研发方面的专业知识与甲骨文在人工智能和医疗健康数据方面的能力，以支持患者匹配和研究工作
初期工作将侧重于癌症、心血管、呼吸系统、免疫学及罕见病领域，同时也有望助力严重疾病的早期诊断
首个项目将与总部位于阿联酋的医疗保健公司M42合作，支持阿布扎比的高血压研究
患者招募仍是临床研究面临的最大挑战之一，招募延迟往往会导致试验周期延长并增加研发成本
过去，不恰当的试验设计也曾给阿斯利康带来困扰，其乳腺癌药物 (link) 的延迟以及神经系统疾病治疗药物 (link) 的失败曾引发一些担忧
阿斯利康正致力于扩大其药品组合，目标是在 2030年前实现超过800亿美元的年收入，并着力解决药物研发中的行业瓶颈

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/hans/news/2676507346"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2676507346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2676507346?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-10-20 15:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676507346","market":"hk","top_or_hot":-1,"title":"阿斯利康与甲骨文合作开展人工智能驱动的临床试验","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>与<a href=\"https://laohu8.com/S/ORCL\">甲骨文</a>合作开展人工智能驱动的临床试验</title></head><body><p><span>路透10月20日</span><span> - </span>阿斯利康（AstraZeneca） <span>AZN.L</span> 周二表示，该公司正与甲骨文（Oracle） <span>ORCL.N</span> 合作，利用人工智能和真实世界数据来筛选符合条件的临床试验患者并监测安全性信号等，以此提升临床研究水平。</p><ul><li><p>此次合作将结合阿斯利康在药物研发方面的专业知识与甲骨文在人工智能和医疗健康数据方面的能力，以支持患者匹配和研究工作</p></li><li><p>初期工作将侧重于癌症、心血管、呼吸系统、免疫学及罕见病领域，同时也有望助力严重疾病的早期诊断</p></li><li><p>首个项目将与总部位于阿联酋的医疗保健公司M42合作，支持阿布扎比的高血压研究</p></li><li><p>患者招募仍是临床研究面临的最大挑战之一，招募延迟往往会导致试验周期延长并增加研发成本</p></li><li><p>过去，不恰当的试验设计也曾给阿斯利康带来困扰，其乳腺癌药物 (<span>link</span>) 的延迟以及神经系统疾病治疗药物 (<span>link</span>) 的失败曾引发一些担忧</p></li><li><p>阿斯利康正<span>致力于扩大其药品组合，目标是在 </span>2030年前实现超过800亿美元的年收入，并着力解决药物研发中的行业瓶颈</p></li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康与甲骨文合作开展人工智能驱动的临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康与甲骨文合作开展人工智能驱动的临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-10-20 15:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>与<a href=\"https://laohu8.com/S/ORCL\">甲骨文</a>合作开展人工智能驱动的临床试验</title></head><body><p><span>路透10月20日</span><span> - </span>阿斯利康（AstraZeneca） <span>AZN.L</span> 周二表示，该公司正与甲骨文（Oracle） <span>ORCL.N</span> 合作，利用人工智能和真实世界数据来筛选符合条件的临床试验患者并监测安全性信号等，以此提升临床研究水平。</p><ul><li><p>此次合作将结合阿斯利康在药物研发方面的专业知识与甲骨文在人工智能和医疗健康数据方面的能力，以支持患者匹配和研究工作</p></li><li><p>初期工作将侧重于癌症、心血管、呼吸系统、免疫学及罕见病领域，同时也有望助力严重疾病的早期诊断</p></li><li><p>首个项目将与总部位于阿联酋的医疗保健公司M42合作，支持阿布扎比的高血压研究</p></li><li><p>患者招募仍是临床研究面临的最大挑战之一，招募延迟往往会导致试验周期延长并增加研发成本</p></li><li><p>过去，不恰当的试验设计也曾给阿斯利康带来困扰，其乳腺癌药物 (<span>link</span>) 的延迟以及神经系统疾病治疗药物 (<span>link</span>) 的失败曾引发一些担忧</p></li><li><p>阿斯利康正<span>致力于扩大其药品组合，目标是在 </span>2030年前实现超过800亿美元的年收入，并着力解决药物研发中的行业瓶颈</p></li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2860962120.EUR","symbol_name":"CPR INVEST - ARTIFICIAL INTELLIGENCE \"A2\" (EUR) ACC A","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261020:nL4T4660EG:1","article_id":"2676507346","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2676507346","pubTimestamp":1792481606,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"阿斯利康与甲骨文合作开展人工智能驱动的临床试验路透10月20日-阿斯利康AZN.L周二表示，该公司正与甲骨文ORCL.N合作，利用人工智能和真实世界数据来筛选符合条件的临床试验患者并监测安全性信号等，以此提升临床研究水平。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2860962120.EUR":"CPR INVEST - ARTIFICIAL INTELLIGENCE \"A2\" (EUR) ACC A","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU2250418816.HKD":"BGF WORLD TECHNOLOGY \"A\" (HKD) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU1642822529.SGD":"THREADNEEDLE (LUX) GLOBAL TECHNOLOGY \"A\" (SGD) ACC","LU0444973449.USD":"CT (LUX) I GLOBAL TECHNOLOGY \"DU\" (USD) ACC","BK4581":"高盛持仓","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","BK4543":"AI","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1823568750.SGD":"Fidelity Global Technology A-ACC SGD","BK4534":"瑞士信贷持仓","OGIG":"ALPS O'Shares Global Internet Giants ETF","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","ORAC":"Corgi ORCL 2x Daily ETF","BK4516":"特朗普概念","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1235294995.USD":"FIDELITY GLOBAL TECHNOLOGY \"A\" (USDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4538":"云计算","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","ORCS":"1倍做空ORCL ETF-Direxion","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","ORCU":"2倍做多ORCL ETF-Direxion","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","LU0861579265.USD":"联博低波幅策略股票基金A","LU1935042215.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC A","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0957808578.USD":"THREADNEEDLE (LUX) GLOBAL TECHNOLOGY \"ZU\" (USD) ACC","IE00BMPRXQ63.HKD":"NEUBERGER BERMAN NEXT GENERATION CONNECTIVITY FUND \"A\" (HKDHDG) ACC","ORCX":"2倍做多ORCL ETF-Defiance","LU0109392836.USD":"富兰克林科技股A","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","ORCZ":"Tradr 2X Short ORCL Daily ETF","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","BK4097":"系统软件","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4585":"ETF&股票定投概念","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU0444971666.USD":"天利全球科技基金","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU1548497426.USD":"安联环球人工智能AT Acc","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0082616367.USD":"摩根大通美国科技A（dist）","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1935043023.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (USD) INC A","BK4588":"碎股","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1935042488.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","IGV":"北美软件ETF-iShares","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","TDIV":"第一信托纳斯达克科技股利指数基金","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0476273544.USD":"CT (LUX) I GLOBAL TECHNOLOGY \"BU\" (USD) ACC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4528":"SaaS概念","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4568":"美国抗疫概念","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","ORCL":"甲骨文","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU1046421795.USD":"富达环球科技A-ACC","AZN":"阿斯利康","BK4007":"制药","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1935043536.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (SGDHDG) INC A","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU1815336760.USD":"THREADNEEDLE (LUX) GLOBAL TECHNOLOGY \"AUP\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0081259029.USD":"UBS (LUX) EQUITY FUND - TECH OPPORTUNITY \"P\" (USD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0056508442.USD":"贝莱德世界科技基金A2","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999001424.SGD":"United E-Commerce Fund SGD"},"translate_title":"AstraZeneca partners with Oracle to conduct AI-driven clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/79283681ac94d0f766b21789d4d49b6e","symbols_score_info":{"ORCZ":0.6,"ORCU":0.6,"ORCL":1.9,"ORAC":0.6,"ORCX":0.6,"OGIG":0.6,"TDIV":0.6,"AZN":1.9,"AZNH":0.6,"SORCLmain":0.6,"ORCS":0.6,"IGV":0.6},"content_text":"<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>与<a href=\"https://laohu8.com/S/ORCL\">甲骨文</a>合作开展人工智能驱动的临床试验路透10月20日 - 阿斯利康（AstraZeneca） AZN.L 周二表示，该公司正与甲骨文（Oracle） ORCL.N 合作，利用人工智能和真实世界数据来筛选符合条件的临床试验患者并监测安全性信号等，以此提升临床研究水平。此次合作将结合阿斯利康在药物研发方面的专业知识与甲骨文在人工智能和医疗健康数据方面的能力，以支持患者匹配和研究工作初期工作将侧重于癌症、心血管、呼吸系统、免疫学及罕见病领域，同时也有望助力严重疾病的早期诊断首个项目将与总部位于阿联酋的医疗保健公司M42合作，支持阿布扎比的高血压研究患者招募仍是临床研究面临的最大挑战之一，招募延迟往往会导致试验周期延长并增加研发成本过去，不恰当的试验设计也曾给阿斯利康带来困扰，其乳腺癌药物 (link) 的延迟以及神经系统疾病治疗药物 (link) 的失败曾引发一些担忧阿斯利康正致力于扩大其药品组合，目标是在 2030年前实现超过800亿美元的年收入，并着力解决药物研发中的行业瓶颈","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}